BOSTON, Oct. 27 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company generated revenues during the three months ended September 30, 2010 in the amount of $134,426 versus $99,710 for the three months ended September 30, 2009. This was an increase of 34.8% for the three months during 2010 as compared to 2009.
Despite a down global economy, Solos has been able to increase its sales transactions due to consistent product orders from the Company’s current customer base. Over the past twelve months, Solos has placed an emphasis on promoting and marketing its MammoView® product line to hospitals and cancer centers. Revenue for the third quarter was driven by sales from the MammoView® line as well as strong sales from its standard product line with increased orders for the Company’s Vascular Clamp System.
“We completed another strong quarter of sales in 2010,” stated Bob Segersten, President of Solos Endoscopy, Inc. “Year-to-date, we have delivered double-digit revenue growth in what continues to be a challenging economic environment.”
The Company expects to post its full unaudited financial results for the three months ended September 30, 2010 on the Pink Sheets OTC Markets website within in the next forty-five days.
Throughout the remainder of 2010, the Company will continue its new product development for the MammoView® product line. In addition, Solos plans to achieve market expansion through its efforts to meet the requirements of the ISO 13485 standard and ultimately obtain the CE Mark and the permission to sell medical devices in the European Union and Canada.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company’s website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.
